Will TP53-mutated AML respond to immunotherapy?November 18, 2019Leukemia, Myelodysplasia, TransplantationImmunotherapyRare Diseases
Better overall survival with nivolumab vs. chemo for advanced ESCCNovember 7, 2019GastroenterologyImmuno-oncologyRare DiseasesGastrointestinal Cancer
Adverse cytogenetics trump molecular risk in NPM1-mutated AMLOctober 15, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
mIDH1 inhibitor ivosidenib improves progression-free survival in advanced cholangiocarcinomaOctober 1, 2019GastroenterologyRare DiseasesGastrointestinal Cancer
FDA approves Turalio for symptomatic tenosynovial giant cell tumorAugust 2, 2019Sarcoma & GISTRare Diseases
Ibrutinib tops chlorambucil against CLLJuly 10, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
R2 appears active in high-risk FL and MZLJune 14, 2019Lymphoma & Plasma Cell DisordersFollicular LymphomaRare Diseases
Pazopanib extended PFS in patients with carcinoid tumorsJune 5, 2019GastroenterologyRare DiseasesGastrointestinal Cancer
Pexidartinib gets ODAC nod for tenosynovial giant cell tumor treatmentMay 15, 2019Sarcoma & GISTRare Diseases
Baseline imaging recommended in all Merkel cell carcinoma patientsMay 13, 2019Nonmelanoma Skin CancerRare Diseases
Researchers propose new risk groups for NK-AMLMay 8, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
FDA approves ivosidenib frontline for certain AML patientsMay 3, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
Idelalisib shows long-term safety, efficacy for relapsed CLLApril 26, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
Tagraxofusp produces high response rate in BPDCNApril 24, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
